Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

A Systematic Review of the Efficacy of KRAS p.G12C Inhibitors in Metastatic Colorectal Cancer: The Current State of Science.

Cancer investigation - 1 May 2026

Boby Jeffrey Mathew, Ilerhunmwuwa Nosakhare, Benny Jame Mathew, Peniche Paola Zinser, Baytar Doga Kahramangil, Sahin Ibrahim Halil

Abstract excerpt

BACKGROUND: KRAS p.G12C (c.34G > T) inhibitors have been reported to have varying survival outcomes in CRC patients across studies. Hence, our review aimed to provide a comprehensive understanding of the efficacy and safety of these agents among the CRC population. METHODS: Major databases, including but not limited to PubMed and Ovid, were searched for original clinical trials assessing the efficacy or safety of...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antineoplastic Agents
Share to Antineoplastic Combined Chemotherapy Protocols

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Cetuximab

Share to Colorectal Neoplasms

Share to Mutation

Share to Neoplasm Metastasis

Share to Proto-Oncogene Proteins p21(ras)

Share to Treatment Outcome

Source

Identifiers

PMID: 41784211
DOI: 10.1080/07357907.2026.2636581

Genes

KRAS
EGFR

Variants

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

A Systematic Review of the Efficacy of KRAS p.G12C Inhibitors in Metastatic Colorectal Cancer: The Current State of Science.PMID 41784211Read ↗

Sotorasib plus Panitumumab in Refractory Colorectal Cancer with Mutated KRAS G12C.Semantic proximity Read ↗

Efficacy and toxicity of KRASG12C inhibitors in advanced solid tumors: a meta-analysis.Semantic proximity Read ↗

Garsorasib, a KRAS G12C inhibitor, with or without cetuximab, an EGFR antibody, in colorectal cancer cohorts of a phase II trial in advanced solid tumors with KRAS G12C mutation.Semantic proximity Read ↗

Targeting KRAS G12C Mutation in Colorectal Cancer, A Review: New Arrows in the Quiver.Semantic proximity Read ↗

Assessment of KRASG12C inhibitors for colorectal cancerSemantic proximity Read ↗

KRAS G12C-mutated Metastatic Colorectal Cancer: Current Therapeutic Strategies and Future Directions.Semantic proximity Read ↗

Prognostic significance of KRAS G12C versus non-G12C RAS mutations in metastatic colorectal cancer: a systematic review and meta-analysis.Semantic proximity Read ↗

Adagrasib in Advanced Solid Tumors Harboring a KRASG12C Mutation.Semantic proximity Read ↗

Sotorasib with panitumumab in chemotherapy-refractory KRASG12C-mutated colorectal cancer: a phase 1b trial.Semantic proximity Read ↗

KRASG12C Inhibition with Sotorasib in Advanced Solid Tumors.Semantic proximity Read ↗

Outcomes following KRASG12C inhibitor treatment in patients with KRASG12C-mutated solid tumors: A systematic review and meta-analysis.Semantic proximity Read ↗

Development of KRAS Inhibitors and Their Role for Metastatic Colorectal Cancer.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.